News >

CLL Paradigm Rapidly Evolving With Novel Agents

Brandon Scalea
Published: Thursday, Oct 25, 2018

Emmanuel S. Antonarakis, MD

Brian T. Hill, MD, PhD
In the past 5 years, there has been a major shift in the treatment of patients with chronic lymphocytic leukemia (CLL), said Brian T. Hill, MD, PhD, with an abundance of novel agents and a diminished role for chemotherapy.

State of the Science Summit™ on Hematologic Malignancies, Hill, assistant professor, hematology and oncology, Cleveland Clinic, discussed some of the recent advances and regulatory decisions in the treatment of patients with CLL.

OncLive: What is the current state of CLL treatment?

Hill: In contrast to the old way of treating, which was chemotherapy and chemoimmunotherapy over and over again with diminishing results, we now have so many highly active and effective agents. It is getting challenging now for general oncologists to figure out how to select from these treatments and how to sequence them.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication